Monoclonal antibodies to malignant human gliomas
- 1 October 1992
- journal article
- review article
- Published by Springer Nature in Molecular and Chemical Neuropathology
- Vol. 17 (2), 137-146
- https://doi.org/10.1007/bf03159988
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor functionBiochemical and Biophysical Research Communications, 1991
- Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomasActa Neuropathologica, 1991
- Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitisBritish Journal of Cancer, 1990
- Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.Proceedings of the National Academy of Sciences, 1990
- Sialyllactotetraosylceramide, a Ganglioside Marker for Human Malignant GliomasJournal of Neurochemistry, 1988
- Potential ganglioside antigens associated with human gliomasNeurological Research, 1986
- Characterization of new gangliosides of the lactotetraose series in murine xenografts of a human glioma cell lineFEBS Letters, 1986
- A novel disialoganglioside (IV3NeuAcIII6NeuAcLc4) of human adenocarcinoma and the monoclonal antibody (FH9) defining this disialosyl structureBiochemistry, 1986
- Sialosyllactotetraosylceramide, a novel ganglioside antigen detected in human carcinomas by a monoclonal antibodyFEBS Letters, 1985
- Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial originNature, 1985